Pfizer Wyeth Collaboration Problems (NYSE:PFE)

From the very first day when Pfizer and Wyeth announced their merger agreement, there has been a lot of commotion in the stock market at the same time concerns about how both this pharmaceutical giants will combine their teams of scientists and others employees working in the R&D unit. Few days earlier Pfizer’s R&D Chief Martin Mackay did make an announcement that the company would now like to cut billions of dollars that are being used for the R&D costs as they now merge their laboratories with Wyeth Pharmaceuticals. This has really led to the tension amongst the employees of Pfizer and the investors as well who are keeping a close watch at the action that will happen sooner or later.

However, Martin Mackay and Mikael Dolston who will head the research departments for their respective companies are looking to come up with a new corporate structure which would combine the best of their R&D staff together rather than choosing the option for lay offs. They have together announced that the new Pfizer will have 18 separate R&D units and that they will make sure that both companies work together instead of working as two separate entities and in isolation. Now analysts and investors are playing a waiting game to see what Pfizer and Wyeth come up with.